Business
Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programmes
Exclusive collaboration and license agreement for the development and global commercialisation of Arbor’s clinical-stage gene editing programme, ABO-101 for primary hyperoxaluria type 1 (PH1)Multitarget research collaboration and option agreement for Arbor’s innovative gene editing technologies for the development of additional rare liver disease targetsArbor eligible to receive up to $115M in upfront and near-term payments, along with $2B in potential development, regulatory and commercial mile
About this update from Arbor Realty Trust
[{"type":"image","alt":"Chiesi Group","displaySize":"","headline":null,"caption":"Chiesi Group","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/5dd1c0acda07ba094ac971872a3d2a39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V8PpVMIszO9D6xxH_DS_yg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5dd1c0acda07ba094ac971872a3d2a39","width":300,"height":200}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Exclusive collaboration and license agreement for the development and global commercialisation of Arbor’s clinical-stage gene editing programme, ABO-101 for primary hyperoxaluria type 1 (PH1)","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"Multitarget research collaboration and option agreement for Arbor’s innovative gene editing technologies for the development of additional rare liver disease targets","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Arbor eligible to receive up to $115M in upfront and near-term payments, along with $2B in potential development, regulatory and commercial milestones and low double-digit tiered royalties for products licensed under the agreements","length":231,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":587,"olType":false},{"type":"text","content":"PARMA, Italy and CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Chiesi Group, an international research-oriented biopharmaceutical company, together with Arbor Biotechnologies, Inc., a next-generation biotechnology company discovering and developing innovative approaches in genetic medicines, today announced an exclusive global collaboration and license agreement for Arbor’s clinical stage programme ABO-101 in PH1 together with a multitarget option agreement for the use of Arbor’s advanced gene editing platform technology to develop novel liver targeted therapies for rare diseases.","length":593,"tagName":"p"},{"type":"text","content":"At Chiesi Group, these programmes are spearheaded by Chiesi Global Rare Diseases, the Group’s dedicated business unit focused on research, development, and commercialisation of therapies for rare and ultra-rare conditions.","length":222,"tagName":"p"},{"type":"text","content":""This collaboration marks a transformative momen...